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Summary Introduction
Neuroﬁbroma is a benign tumor that arises from small Neuroﬁbromas are benign tumors that originate from a
or large nerves. This neoplastic lesion is a common fea- peripheral nerve sheath. They are primarily composed
ture of neuroﬁbromatosis type 1 (NF1), one of the most of Schwann cells and ﬁbroblasts, but a mixture of other
common autosomal dominant disorders. The NF1 gene different cell types are also present (mast cells, endothe-
codes for a protein called ‘‘neuroﬁbromin.’’ It possesses lial cells, perineural cells, pericytes, and a small number
a region that shares a high homology with the family of of nerve cells) (revised in Riccardi 1992). Neuroﬁbromas
GTPase-activating proteins, which are negative regula- are also one of the most frequent features of neuroﬁ-
tors of RAS function and thereby control cell growth bromatosis type 1 (NF1), or von Recklinghausen dis-
and differentiation. The evidence points to the NF1 gene ease, and they constitute an important diagnostic crite-
being a tumor-suppressor gene. NF1 patients also have rion of this complex genetic disorder. NF1 is a common
an increased incidence of certain malignant tumors that autosomal dominant disease in man, with an incidence
are believed to follow the ‘‘two hit’’ hypothesis, with of Ç1/3,500. It is a multisystemic disease, although the
one allele constitutionally inactivated and the other so- nerve system and the skin are the tissues mainly affected.
matically mutated. Recently, somatic loss of heterozy- Apart from the development of neuroﬁbromas, cafe´-au-
gosity (LOH) has been described for neuroﬁbromas, and lait spots, axillary freckles, and Lisch nodules of the iris
mutations in both copies of the NF1 gene have been constitute the most common clinical features of NF1.
reported for a dermal neuroﬁbroma. The aim of our Approximately 2%–6% of NF1 patients develop malig-
study was the analysis of the NF1 locus in benign neuro- nant tumors (revised in Riccardi 1992). The NF1 gene
ﬁbromas in NF1 patients. We performed LOH analysis is located in the pericentromeric region of human chro-
on 60 neuroﬁbromas belonging to 17 patients, 9 of them mosome 17 (17q11.2), contains 60 exons, and produces
with family history of the disease and 8 of them spo- an 11–13-kb ubiquitously expressed transcript that en-
radic. We have analyzed ﬁve intragenic NF1 markers codes for a protein called ‘‘neuroﬁbromin’’ (Cawthon
and six extragenic markers, and we have found LOH in et al. 1990; Viskochil et al. 1990; Wallace et al. 1990;
25% of the neuroﬁbromas (corresponding to 53% of Li et al. 1995). Until now, only one clear functional
the patients). In addition, we found that in the neuroﬁ- domain has been attributed to neuroﬁbromin (Martin
bromas of patients from familial cases the deletions oc- et al. 1990). This domain consists of 360 amino acids
curred in the allele that is not transmitted with the dis- of the predicted gene product and shows homology to
ease, indicating that both copies of the NF1 gene were the catalytic domain of the mammalian GTPase-activat-
inactivated in these tumors. Therefore, the recent re- ing protein (GAP) and the products of the yeast IRA1
ports mentioned above, together with our ﬁndings, and IRA2 genes, which can down-regulate p21ras activ-
strongly support the double inactivation of the NF1 gene ity (Ballester et al. 1990; Xu et al. 1990a, 1990b). This
in benign neuroﬁbromas. region is called the ‘‘NF1 GAP related domain’’ (NF1-
GRD) and is located in the central portion of the NF1
gene, encompassing exons 21–27a (Li et al. 1995). So-
matic mutations in the NF1 gene have been described
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tion of neuroﬁbromas. Preliminary studies failed to ﬁnd immersed in liquid nitrogen. A part of each tumor was
separated and completely defrosted. Tumor tissueloss of heterozygosity (LOH) in neuroﬁbromas (Menon
et al. 1990; Glover et al. 1991; Skuse et al. 1991; Lothe (nearly always yellowish and well circumscribed), sur-
rounding tumor tissue, and skin were carefully separatedet al. 1995), whereas LOH was found in the analysis of
malignant NF1-related tumors (Skuse et al. 1989; Legius (according to the different morphology of each of these
parts) with a scalpel. Each tissue was carefully slicedet al. 1993). In addition, the presence of both alleles of
the NF1 gene has been described in Schwann cells de- prior to digestion (Wu et al. 1995). DNA was extracted
from each of these components, as described by Wurived from neuroﬁbromas (Stark et al. 1995). However,
recent investigations report the ﬁnding of (1) somatic et al. (1995). Moreover, DNA from peripheral blood
lymphocytes of each patient was extracted by the ‘‘salt-NF1 deletions in benign neuroﬁbromas (Colman et al.
1995) and (2) mutations in both copies of the NF1 gene ing out’’ method (Miller et al. 1988).
in a dermal neuroﬁbroma (Sawada et al. 1996). Further-
more, genetic instability in the analysis of several micro- Analysis of LOH
satellite markers has been reported in neuroﬁbromas To investigate LOH, tumoral DNA and nontumoral
(Ottini et al. 1995). DNA from different tissues of the same patient were
It is thought that, at the cellular level, neuroﬁbromas compared. PCR was performed, amplifying several in-
have a unicellular origin (Skuse et al. 1991). Classically, tragenic NF1 loci (RFLP exon 5, IVS27AAAT2.1, IV-
it has been considered that Schwann cells are the progen- S27AC28.4, IVS27AC33.1, and IVS38GT53.0) and
itors of neuroﬁbromas (Waggener 1966; Kamata 1978; four markers ﬂanking the NF1 gene (D17S33, D17S57,
Stefansson et al. 1982), but recent studies have ques- D17S73, and D17S250). Tumors that showed LOH for
tioned this assessment, highlighting the crucial role of D17S250 (the most telomeric marker) were further ana-
ﬁbroblasts in the development of these benign neoplasias lyzed with markers D17S787 (17q22), D17S789
(Rosenbaum et al. 1995). (17q24.3), and D17S785 (17q25.1) (Dib et al. 1996,
The aim of this study was to elucidate the role of pp. A102–A107), in order to determine the extent of
the NF1 gene in the pathogenesis of neuroﬁbromas, by deletions (data not shown). The genetic distances be-
searching for deletions involving the NF1 gene. Sixty tween these telomeric markers are approximately as fol-
peripheral neuroﬁbromas belonging to 17 NF1 patients, lows: NF1–10 cM–D17S250–17 cM–D17S787–15
9 of which had a family history of the disease, were cM–D17S789–16 cM–D17S785. Two markers (introns
studied. We analyzed 11 intragenic and extragenic NF1 1 and 6) within the P53 gene were also analyzed. Six
DNA markers located in chromosome 17, and we found markers corresponded to microsatellite polymorphisms,
LOH in 25% of the neuroﬁbromas (corresponding to and the remainder were RFLPs (ﬁg. 1). The analysis
53% of the patients). In addition, we found that dele- of all these markers was performed as described in the
tions in neuroﬁbromas from six patients with familial Genome Database (GDB), and the genetic distances be-
NF1 occurred in the allele that is not transmitted with tween markers within the NF1 region have been revised
the disease, indicating that both copies of the NF1 gene by La´zaro et al. (1996) (D17S33, D17S57, andD17S73)
were inactivated. These data indicate that the inactiva- and by Friedman et al. (1995) and Rogers et al. (1995)
tion of both copies of the NF1 gene could be a crucial (D17S250) and are also shown in ﬁgure 1. PAGE was
step in the development of benign neuroﬁbromas. performed with PCR products. Microsatellites were sep-
arated in 5% denaturing gels, and RFLPs were sepa-
Patients, Material, and Methods rated, after previous digestion, in 10% nondenaturing
gels. DNA bands were detected by silver staining. SomePatient Identiﬁcation and Sample Acquisition
of these markers (IVS27AAAT2.1, IVS27AC28.4,
Patients were diagnosed according to the accepted
IVS27AC33.1, IVS38GT53.0, and D17S250) were also
standard NF1 diagnostic criteria. They were informed
analyzed by ﬂuorescence by use of an automatic geneticabout the study, and consent was obtained from all of
analyzer (Perkin-Elmer ABI PRISMTM 310).them. Neuroﬁbromas were obtained from 17 patients;
among these patients, there were 9 cases with family
Conﬁrmation of Deletionshistory, and 8 were due to de novo mutations. Sixty
When LOH for a given marker was found, the analy-neuroﬁbromas were obtained, and the diagnosis was
sis was repeated several times, in order to conﬁrm theconﬁrmed by histopathological examination.
deletion. When results were not clear, a second DNA
Sample Processing extraction from the same frozen tumor was performed.
If the ﬂuorescent primers were available, the analysisNeuroﬁbromas were obtained after surgery. A sample
was performed both by ﬂuorescence by use of an auto-from each tumor was sectioned, stained, and examined
by an experienced dermatologist, and the remainder was matic genetic analyzer and by PAGE and silver staining.
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Figure 1 Ideogram of chromosome 17, showing DNA markers studied. Distance between markers located in the NF1 region is given in
centimorgans (cM). The nine patients showing deletions are indicated in uppercase letters (CSG, CLJ, CAG, MIGS, MAPT, CSN, NGL, SLC,
and MOPT). The corresponding neuroﬁbromas are indicated, by numbers, below them. Black squares denote LOH, gray-shaded squares denote
uninformative loci, and white squares denote undeleted regions. Seven neuroﬁbromas (CSG1, CSG2, CSG4, and CSG5 and CSN1, NGL1, and
SLC1) lost the entire 17q arm (data not shown).
Results ning the whole long arm of chromosome 17 were ana-
lyzed (see Patients, Material, and Methods). LOH wasA total of 60 peripheral neuroﬁbromas were analyzed
observed for these three markers in the seven tumorsby use of 11 markers located on chromosome 17 (ﬁg.
analyzed, indicating the loss of the 17q arm telomeric1); all the patients were informative for several of the
to NF1. Moreover, for two neuroﬁbromas (CLJ2 andmarkers used (two patients for nine loci, two patients
SLC1), the deletion detected included several kilobasesfor eight loci, ﬁve patients for seven loci, two patients
upstream of the NF1 gene, indicated by loss of D17S33,for six loci, two patients for ﬁve loci, and four patients
which is situated 1 cM proximal to the NF1 gene (re-for four loci). LOH for one or more markers was de-
vised in La´zaro et al. 1996). None of the neuroﬁbromastected in 15 neuroﬁbromas from nine patients (ﬁgs. 1
that were informative for markers within the P53 geneand 2). Therefore, the percentage of somatic deletions
exhibited deletions in this region (ﬁg. 1).in neuroﬁbromas found in this study was 25% (corre-
Six of the patients showing deletions in the neuroﬁ-sponding to 53% of patients). LOH was not found in
bromas were familial cases and belonged to four inde-DNA from blood, skin, or surrounding normal tissue
pendent kindred (ﬁg. 3). In these families it was possibleseparated from neuroﬁbromas. When DNA markers
to assess the chromosome 17 segregating with the dis-were visualized by PAGE, the intensity of the band
ease, and it was found that the deletions in the neuroﬁ-showing LOH was variable among neuroﬁbromas. This
bromas occurred in the non–NF1-associated chromo-phenomenon was probably due to the different percent-
some (ﬁg. 3).ages of the cell type carrying the deletion in each neuro-
ﬁbroma. Table 1 depicts, for each patient with at least
Discussionone neuroﬁbroma with LOH, the number of informative
loci, the total number of neuroﬁbromas resected versus Data have emerged indicating that inactivation of
both copies of a tumor-suppressor gene could be in-the number of neuroﬁbromas with LOH, and the body
location of both. volved in the development of benign tumors (Ichii et al.
1992; Colman et al. 1995; De Vitis et al. 1996; SawadaAmong the 15 neuroﬁbromas with LOH, 10 tumors
(CSG1–CSG5, CLJ1 and CLJ2, MIGS1, SLC1, and et al. 1996). Our study strongly supports the idea that
inactivation of both copies of the NF1 gene also occursMOPT1) seem to lose the whole NF1 gene (or at least
exons 5–38). In seven neuroﬁbromas (CSG1, CSG2, in benign neuroﬁbromas. This ﬁnding already had been
presented by Colman et al. (1995), in a similar interest-CSG4, and CSG5 and CSN1, NGL1, and SLC1) LOH
for D17S250 (the most telomeric marker used in the ing study. They found somatic deletions in several neu-
roﬁbromas from sporadic NF1 patients. Because of bothpresent study) was detected. This marker is situated 10
cM distal to the NF1 gene (Friedman et al. 1995; Rogers the impossibility of performing linkage studies in these
patients and the failure to ﬁnd their constitutional muta-et al. 1995). In order to determine the extend of these
deletions, three additional microsatellite markers span- tions, the double inactivation of the NF1 gene in neuro-
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The molecular analysis of the 60 neuroﬁbromas pre-
sented here revealed in 25% of them the existence of
LOH for the region containing the NF1 gene. This ﬁgure
is signiﬁcantly different from the percentage of germinal
large deletions described thus far in the NF1 gene
(Ç15% of reported mutations in the NNFF Consortium
[revised in Shen et al. 1996]). This difference could re-
ﬂect a distinct mutation mechanism in germ-line versus
somatic cells, the latter being more prone to deletion.
Regarding the 75% of neuroﬁbromas that did not show
LOH, we believe that most of them will harbor, within
the NF1 gene, another somatic mutation, which is not
detectable by the approach used in this study. Thus, we
think that the majority of neuroﬁbromas from NF1
patients carry two mutated NF1 copies. In support of
this idea, we found that, in the neuroﬁbromas of patients
from the familial cases, the deletions occurred in the
allele that is not transmitted with the disease (ﬁg. 3),
indicating that both copies of the NF1 gene were inacti-
vated in these tumors. These results suggest lack of neu-
roﬁbromin function in these neuroﬁbromas. When this
statement is considered together with the fact that cuta-
neous neuroﬁbromas essentially never transform to ma-
lignancy, it is reasonable to think that the absence of
neuroﬁbromin can deregulate cell proliferation in this
tissue, albeit not to the extent of malignancy.
The size of deletions found varies, but, at least in nine
neuroﬁbromas, it seems to be large, probably removing
the whole gene. Furthermore, in 7 of the 15 NF1-deleted
tumors, LOH affects the whole 17q arm telomeric to
NF1. This fact is in agreement with the results presented
by Colman et al. (1995), in which four of eight neuroﬁ-
bromas with LOH had lost the telomeric markers ana-
lyzed. It is interesting to mention that, in most of cases,
deletions seems to be restricted to the 5 region of the
NF1 and not to the 3 region. So, LOH appears not to
Figure 2 Allelic losses in several neuroﬁbromas, for the markers involve the centromeric region but can affect the re-
indicated. A, Top, Fluorescence analysis of markers IVS38GT53.0,
maining part of the 17q arm. The region encompassingIVS27AC28.4, and D17S250 of patient CSG. In the left-hand panel,
exons 28–38 is deleted in most of the tumors, at leastLOH is shown (arrow) in tumor T5 (IVS38GT53.0 and IV-
S27AC28.4), and T11 is shown as a tumor without LOH. In the right- in 11 of them. Three possible reasons could explain this
hand panel, LOH is shown in tumor T1 (D17S250), and T9 is shown ﬁnding. One reason is that this region has been saturated
as a tumor without LOH. Bottom, Silver-staining detection of the with polymorphic markers, making the detection of de-
same markers. Only blood and tumors with LOH (arrowhead) are
letions easier. Another reason could be the existence ofshown. B, Silver-staining detection of marker IVS27AC28.4 from
some speciﬁc sequences in these region, which facilitateblood, skin, and neuroﬁbroma of patient CAG. A loss of the larger
allele is detected only in the DNA belonging to the neuroﬁbroma. C, the rearrangements found, already suggested by Upad-
Top, Silver-staining detection of marker pHHH202/RsaI (D17S33) in hyaya et al. (1994). And, last, it could be that in this
patient SLC. Bottom, Silver-staining detection of markers IV- part of the gene a domain exists that plays an important
S27AC33.1 and IVS38GT53.0 in patient MOPT. LOH is shown (ar-
role in neuroﬁbroma development. It is worth notingrowheads).
that intron 27b is deleted in 13 of 15 tumors with NF1
deletions. This intron spans ú40 kb and has three genes
(EVI2A, EVI2B, and OMGP) embedded within itﬁbromas could not be completely demonstrated. Never-
theless, Sawada et al. (1996) have recently described the (Viskochil et al. 1990). There is the possibility that these
genes could be related to either the development of neu-double inactivation of the NF1 gene in one neuroﬁ-
broma from an NF1 individual who has a large germ- roﬁbromas or the generation of these large deletions.
Other studies have failed to ﬁnd LOH for the NF1line NF1-gene deletion.
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Table 1
Number of Tumors, Body Location, and Genetic Information for Patients with at Least One Neuroﬁbroma Showing LOH
No. of Neuroﬁbromas Location of
No. of with LOH/No. of Neuroﬁbromas
Patient Informative Loci Neuroﬁbromas Studied Neuroﬁbroma Location(s) with LOH
CSG 7 6/16 Trunk Trunk
CLJ 7 2/9 Trunk, back, mammary aureole Back
CAG 4 1/6 Back, right inferior extremity Back
MIGS 7 1/1 Back Back
MAPT 8 1/3 Left thigh, mammary aureole, trunk Mammary aureole
CSN 9 1/1 Inferior part of the leg Inferior part of the leg
NGL 6 1/1 Trunk Trunk
SLC 7 1/3 Left and right forearm Left forearm
MOPT 8 1/3 Right lumbar, left arm, left thigh Left arm
gene in neuroﬁbromas (Menon et al. 1990; Glover et al. be easily produced, because of the low DNA amount
usually obtained from parafﬁn-embedded samples,1991; Skuse et al. 1991; Lothe et al. 1995), but several
reasons could explain this. Because neuroﬁbromas are which could facilitate the generation of artifacts that can
be confused with instability (M. A. Peinado, personalcomposed of an admixture of cell types, a complete
absence of the deleted allele is not expected, and its communication). We believe that, if 50% of neuroﬁ-
bromas had genomic instability, as they had reported,detection will depend on the percentage of the speciﬁc
cell type having the deletion, in comparison with the we would be able to detect it in our samples.
Studies on the variation in expression of NF1 showedremaining cells that constitute the neuroﬁbroma. More-
over, if either inﬁltration of normal tissues or incomplete that the number of cutaneous neuroﬁbromas had a high
correlation between MZ twins and that this correlationremoval during dissection occurs, the presence of a dele-
tion will be greatly obscured. In addition, our ﬁndings decreased when the distance between relatives increased
(Easton et al. 1993). This ﬁnding suggested both a minorsuggest that Ç25% of the neuroﬁbromas have large de-
letions, making it necessary to screen a large number role of the NF1 type mutation and the existence of other
speciﬁc trait-modifying genes (Easton et al. 1993). Theof neuroﬁbromas with several informative markers, in
order to identify somatic deletions. ﬁnding that some neuroﬁbromas show double inactiva-
tion of the NF1 gene allows us to consider these tumorsInstability in the analysis of microsatellite markers in
neuroﬁbromas has recently been reported (Ottini et al. as partial knockouts for this gene. One remarkable ﬁnd-
ing of this study is that 66.6% of the familial cases1995). Nevertheless, by analyzing six microsatellite
markers in our sample consisting of 60 neuroﬁbromas, of NF1 show deletions of the NF1 gene in the benign
neuroﬁbromas, always occurring in the NF1 allele thatwe have not been able to detect any alteration. Further-
more, the usefulness of these microsatellite markers in does not segregate with the disease. This study strongly
supports the hypothesis that most neuroﬁbromas havethe detection of instabilty was tested. Pairs of normal
and tumoral colorectal tissue in which instability was both copies of the NF1 gene inactivated. Therefore, they
could be a good model for study of the differential ex-known (provided by Dr. M. A. Peinado) were screened
by use of these markers. Instability was detected with pression of other genes involved in the formation and
proliferation of neuroﬁbromas, providing some insightsall of them (data not shown), indicating their reliability
for this purpose, even though (1) these are not the same into the mechanisms and functions of neuroﬁbromin
both in the disease and in the neoplastic processes.markers as were used byOttini et al. (1995) and (2) there
could be sensitivity differences between them. Thus, this The two-hit model for neoplasia (Knudson 1971) has
been demonstrated in other benign tumors, such as ade-molecular mechanism seems not to be involved in the
origin of the neuroﬁbromas screened in the present nomas (Ichii et al. 1992), meningiomas (De Vitis et al.
1996), and others. It is reasonable to assume that thestudy. One possible explanation for this difference could
be geographical genetic variances between the popula- number of genes involved in the generation of benign
neoplasias would be less than that in malignancies, astion studied by Ottini et al. (1995) and our population.
Another possibility is that our samples were from fresh is known for the development of colorectal tumor
(Fearon and Vogelstein 1990). Thus, the study of benigntumors, whereas the tumors used by Ottini et al. (1995)
were extracted from parafﬁn-embedded sections. Incon- tumors should facilitate the search for molecular mecha-
nisms causing neoplasias. A great number of tumorssistencies in the analysis of microsatellite markers could
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Figure 3 Pedigrees of the six familial NF1 cases in which LOH was found in at least one neuroﬁbroma. Haplotypes of markers within
the NF1 region are indicated below the symbol in the pedigree. Uninformative markers are denoted by ‘‘U.’’ The haplotype associated with
the disease is boxed. The haplotypes of some neuroﬁbromas of each patient are also shown. In all of the neuroﬁbromas in which LOH was
detected (arrows), the deletion was found in the non–NF1-associated chromosome.
/ 9a35$$se11 08-25-97 17:46:33 ajhga UC-AJHG
518 Am. J. Hum. Genet. 61:512–519, 1997
ﬁbromas in type 1 neuroﬁbromatosis (NF1) show somaticarise from neural crest derivatives. The comparative
deletions of NF1 gene. Nat Genet 11:90–92study of such tumors could be useful to elucidate the
De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P,genes and mechanisms controlling the development of
Bigozzi U, Montali E, et al (1996) Screening for mutationsthese tissue-speciﬁc tumors.
in the neuroﬁbromatosis type 2 (NF2) gene in sporadic me-Controversial data have emerged related to the contri-
ningiomas. Hum Genet 97:632–637
bution of the different cell types in the genesis of neuro- Dib C, Faure´ S, Fizames C, Samson D, Drouot N, Vignal A,
ﬁbromas (Waggener 1966; Kamata 1978; Stefansson et Millasseau P, et al (1996) A comprehensive genetic map of
al. 1982; Rosenbaum et al. 1995). It would be of great the human genome based on 5264 microsatellites. Nature
interest to ﬁnd which cell type carries the genetic alter- 380:A102–A107
ations causing neuroﬁbroma formation. The fact that Easton DF, Ponder MA, Huson SM, Ponder BAJ (1993) An
analysis of variation in expression of neuroﬁbromatosisseveral neuroﬁbromas show LOH for the NF1 gene
(NF) type 1 (NF1): evidence for modifying genes. Am J Humcould be useful for this purpose. Once the different cell
Genet 53:305–313types are isolated from neuroﬁbromas in which LOH
Fearon ER, Vogelstein B (1990) A genetic model for colorectalhas been detected, deletions can be used as internal
tumorigenesis. Cell 61:757–767markers to recognize which is the cell type harboring
Friedman TB, Liang Y, Weber JL, Hinnant JT, Barber TD,the LOH. It will also be interesting to study neuroﬁ-
Winata S, Arhya IN, et al (1995) A gene for congenital,
bromas from patients without all the diagnostic criteria recessive deafness DFNB3 maps to the pericentromeric re-
of NF1, to discover whether they follow the same molec- gion of chromosome 17. Nat Genet 9:86–91
ular mechanism. In Gorlin syndrome, for instance, it has Glover TW, Stein CK, Legius E, Andersen LB, Brereton A,
been found that LOH is signiﬁcantly less common in Johnson S (1991) Molecular and cytogenetic analysis of tu-
sporadic cysts than in hereditary cysts (Levanat et al. mors in von Recklinghausen neuroﬁbromatosis. Genes
Chromosom Cancer 3:62–701996). Finally, further studies should be performed to
Ichii S, Horii A, Nakatsuru S, Furuyama J, Utsunomiya J,elucidate the spectrum of NF1 mutations present in neu-
Nakamura Y (1992) Inactivation of both APC alleles in anroﬁbromas, in order to assess whether the double inacti-
early stage of colon adenomas in a patient with familialvation of this gene is a general rule for the development
adenomatous polyposis (FAP). Hum Mol Genet 1:387–390of these tumors.
Kamata Y (1978) Study of the ultrastructure and acetylcholin-
esterase activity in von Recklinghausen’s neuroﬁbromatosis.
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